⚡ Live Signal Feed
122 signals · Ranked by priority · Clinical research + community sentiment
Priority = sentiment strength × evidence quality (max 99) · Community signals capped at "Moderate"
122
Total Signals
All sources combined
100
🔬 Clinical/Research
Peer-reviewed + gov sources
22
🗣 Community
Reddit & forum discussions
44
🇺🇸 US Signals
US-sourced intelligence
34
🇨🇦 Canada Signals
Canada-specific coverage
4 Signals · Sorted by Priority80–99 = high impact · 60–79 = notable · below = monitoring
🇺🇸 US⚡ Testosterone↑ PositiveModerate
NIH research reviewing 103 men post-radical prostatectomy found TRT does not appear to increase cancer recurrence. This provides reassurance for hypogonadal men with treated prostate cancer.
91
Priority
High
🇺🇸 US⚡ Testosterone↓ Risk SignalModerate
Public Citizen formally requested the FDA restore boxed warnings for cardiovascular risks on testosterone products and halt expanded indications without independent studies. This reflects ongoing safety concerns among consumer health advocates.
80
Priority
Notable
🇺🇸 US⚡ Testosterone↓ Risk SignalModerate
US Pharmacist reports significant interest in TRT among younger men, with 14% having used testosterone products. This demonstrates growing demand that may outpace evidence-based clinical indications.
76
Priority
Notable
🇺🇸 US⚡ TestosteronePeer-Reviewed
On December 10, 2025, the FDA hosted leading experts to evaluate testosterone therapy evidence and potential regulatory changes. This signals possible tightening of TRT oversight in the US market.
69
Priority
Monitor